| 产品编号 |
产品名称 |
产品包装 |
产品价格 |
| SF2708-10mM |
CHIR-99021 (GSK-3抑制剂) |
10mM |
233.00元 |
化学信息：
|
化学名
|
6-[2-[[4-(2,4-dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)pyrimidin-2-yl]amino]ethylamino]pyridine-3-carbonitrile
|
|
|
简称
|
CHIR-99021
|
|
别名
|
Chir 99021, Chir-99021, Chir99021, CT 99021, CT-99021, CT99021
|
|
中文名
|
N/A
|
|
化学式
|
C22H18Cl2N8
|
|
分子量
|
465.34
|
|
CAS号
|
252917-06-9
|
|
纯度
|
98%
|
|
溶剂/溶解度
|
Water<1mg/ml; DMSO78mg/ml; Ethanol<1mg/ml
|
|
溶液配制
|
5mg加入1.07ml DMSO，或者每4.65mg加入1ml DMSO，配制成10mM溶液。SF2708-10mM用DMSO配制。
|
生物信息：
|
产品描述
|
CHIR-99021 (CT99021)是一种GSK-3α和GSK-3β抑制剂，IC50分别为10nM和6.7nM。
|
|
信号通路
|
PI3K/Akt/mTOR; Stem Cells & Wnt
|
|
靶点
|
GSK-3β
|
GSK-3α
|
－
|
－
|
－
|
|
IC50
|
6.7nM
|
10nM
|
－
|
－
|
－
|
|
体外研究
|
CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs CDC2 and ERK2, as well as other protein kinases. Furthermore, CHIR-99021 shows only weak binding to a panel of 22 pharmacologically relevant receptors and little inhibitory activity against a panel of 23 nonkinase enzymes. CHIR-99021 induces the activation of glycogen synthase (GS) in insulin receptor-expressing CHO-IR cells with EC50 of 0.763μM.
|
|
体内研究
|
Oral administration of CHIR-99021 at 30mg/kg enhances glucose metabolism in a rodent model of type 2 diabetes, with a maximal plasma glucose reduction of nearly 150mg/dl 3-4 hours after administration, while plasma insulin remains at or below control levels. Oral administration of CHIR-99021 at 16 or 48mg/kg 1 hour before oral glucose challenges in ZDF rats significantly improves glucose tolerance with 14% and 33% reduction in plasma glucose at 16mg/kg and 48mg/kg, respectively, and the higher dose of CHIR-99021 also reduces hyperglycemia before the oral glucose challenge.
|
|
临床实验
|
N/A
|
|
特征
|
N/A
|
相关实验数据(此数据来自于公开文献，碧云天并不保证其有效性)：
|
酶活性检测实验
|
|
方法
|
N/A
|
|
细胞实验
|
|
细胞系
|
Insulin receptor-expressing CHO-IR cells; Primary rat hepatocytes
|
|
浓度
|
0.01-10μM
|
|
处理时间
|
30 min
|
|
方法
|
CHO-IR cells expressing human insulin receptor are grown to 80% confluence in Hamm's F12 medium with 10% fetal bovine serum and without hypoxanthine. Trypsinized cells are seeded in 6-well plates at 1×106 cells/well in 2ml of medium without fetal bovine serum. After 24h, medium is replaced with 1 ml of serum-free medium containing GSK-3 inhibitor or control (final DMSO concentration <0.1%) for 30 min at 37℃. Cells are lysed and centrifuged 15 min at 4℃/14000g. The activity ratio of GS is calculated as the GS activity in the absence of glucose-6-phosphate divided by the activity in the presence of 5mMol/l glucose-6-phosphate, using the filter paper assay of Thomas et al.
|
|
动物实验
|
|
动物模型
|
Female db/db mice; Male ZDF rats
|
|
配制
|
HCl salts formulated
|
|
剂量
|
8-48mg/kg
|
|
给药方式
|
oral administration
|
参考文献：
1. Ring DB, et al. Diabetes. 2003, 52(3), 588-595.
包装清单：
|
产品编号
|
产品名称
|
包装
|
|
SF2708-10mM
|
CHIR-99021 (GSK-3抑制剂)
|
10mM×0.2ml
|
|
SF2708-5mg
|
CHIR-99021 (GSK-3抑制剂)
|
5mg
|
|
SF2708-25mg
|
CHIR-99021 (GSK-3抑制剂)
|
25mg
|
|
—
|
说明书
|
1份
|
保存条件：
-20℃保存，至少一年有效。5mg和25mg包装也可室温保存，至少6个月有效。如果溶于非DMSO溶剂，建议分装后-80℃保存，预计6个月内有效。
注意事项：
本产品对人体有毒，操作时请特别小心，并注意有效防护以避免直接接触人体或吸入体内。
本产品仅限于专业人员的科学研究用，不得用于临床诊断或治疗，不得用于食品或药品，不得存放于普通住宅内。
为了您的安全和健康，请穿实验服并戴一次性手套操作。